Siemion Altman
University of British Columbia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Siemion Altman.
Biological Psychiatry | 2003
Steven G. Potkin; Larry Alphs; Chuanchieh Hsu; K. Ranga Rama Krishnan; Ravi Anand; Frederick Young; Herbert Y. Meltzer; Alan I. Green; Saide Altinsan; Siemion Altman; Likiana Avigo; Richard Balon; Vanda Benešová; Luis Bengochea; István Bitter; Elisabeth Bokowska; Bernardo Carpiniello; Daniel E. Casey; Giovanni B. Cassano; James C.-Y. Chou; Guy Chouinard; Libor Chvila; Jean Dalery; Pedro L. Delgado; Liliana Dell'Osso; Carl Eisdorfer; Robin Emsley; Thomas Fahy; Vera Folnegovic; Sophie Frangou
BACKGROUND Enhanced ability to reliably identify risk factors for suicidal behavior permits more focused decisions concerning treatment interventions and support services, with potential reduction in lives lost to suicide. METHODS This study followed 980 patients at high risk for suicide in a multicenter prospective study for 2 years after randomization to clozapine or olanzapine. A priori predictors related to diagnosis, treatment resistance, and clinical constructs of disease symptoms were evaluated as possible predictors of subsequent suicide-related events. RESULTS Ten baseline univariate predictors were identified. Historical predictors were diagnosis of schizoaffective disorder, history or current use at baseline of alcohol or substance abuse, cigarette smoking, number of lifetime suicide attempts, and the number of hospitalizations in the previous 36 months to prevent suicide. Predictive clinical features included greater baseline scores on the InterSePT scale for suicidal thinking, the Covi Anxiety Scale, the Calgary Depression Scale (CDS), and severity of Parkinsonism. Subsequent multivariate analysis revealed the number of hospitalizations in the previous 36 months, baseline CDS, severity of Parkinsons, history of substance abuse, and lifetime suicide attempts. Clozapine, in general, was more effective than olanzapine in decreasing the risk of suicidality, regardless of risk factors present. CONCLUSIONS This is the first prospective analysis of predictors of suicide risk in a large schizophrenic and schizoaffective population judged to be at high risk for suicide. Assessment of these risk factors may aid clinicians in evaluating risk for suicidal behaviors so that appropriate interventions can be made.
Schizophrenia Research | 2003
Jean-Pierre Lindenmayer; Pál Czobor; Larry Alphs; Ann Marie Nathan; Ravi Anand; Zahur Islam; James C Y Chou; Saide Altinsan; Siemion Altman; Likiana Avigo; Richard Balon; Vanda Beněsová; Luis Bengochea; Alberto Bertoldi; Elisabeth Bokowska; Marc Bourgeois; Bernardo Carpiniello; James C.-Y. Chou; Guy Chouinard; Libor Chvila; Jean Dalery; Liliana Dell'Osso; Carl Eisdorfer; Robin Emsley; Thomas Fahy; Vera Folnegovic; Sophie Frangou; Pedro Gargoloff; Alberto Giannelli; Alan I. Green
BACKGROUND The InterSePT Scale for Suicidal Thinking (ISST) is a 12-item instrument for the assessment of current suicidal ideation in patients with schizophrenia and schizoaffective disorders. We report the psychometric characteristics of this new scale based on two studies. METHOD In Study 1, 22 inpatients with schizophrenia and schizoaffective disorders, who had recently attempted suicide or engaged in suicidal ideation, were rated by three trained independent raters to examine interrater reliability. In Study 2, a total of 980 patients with schizophrenia or schizoaffective disorder with a history of suicidal ideation in the past 36 months were enrolled in a 2-year industry-sponsored suicide prevention study. At baseline, these patients were administered the ISST and the Clinical Global Impression Scale for Severity of Suicidality (CGI-SS) by the Principal Investigator (PI) and by a blinded rater (BR), who also administered the Positive and Negative Symptom Scale (PANSS), the Calgary Depression Scale (CDS), and the Scale of Functioning (SOF). Indices of internal reliability, construct and discriminant validity were examined. RESULTS The intraclass correlation coefficient (ICC) for the total ISST score for the 22 subjects in Study 1 was 0.90 and mean weighted item kappa coefficients ranged from 0.66 to 0.92. In Study 2, internal reliability (Cronbach alpha) was high, ranging from 0.86 to 0.89 for the individual items, and the overall Cronbach alpha coefficient for all items was 0.88. The ISST (PI) total score was highly correlated with the CGI-SS by the blind rater (r = 0.61, p < 0.0001). ISST total scores significantly differentiated the different levels of CGI-SS (F = 519.2; p < 0.0001). Results of construct and discriminant validity analyses are also presented. CONCLUSION The ISST is a reliable and valid instrument for the assessment of current suicidal thinking in patients with schizophrenia and schizoaffective disorder by both clinicians and researchers.
Journal of Nervous and Mental Disease | 2001
Thomas S. Ehmann; Geoffrey N. Smith; Aiko Yamamoto; Natalia Mccarthy; Deborah Ross; Tin Au; Sean W. Flynn; Siemion Altman; William G. Honer
This study sought to: a) ascertain the effect on rates of violence by varying its operational definition and b) compare characteristics of violent and nonviolent patients. Aggressive behavior was recorded daily for every patient (N = 78) during a 2-year period. Standardized rating scales were used to rate psychopathology and functioning. Almost two thirds of patients were aggressive to others, and 26% violently assaulted another person. Official incident reports underestimated rates of violence to others, self- harm, and property damage. Multivariate predictive models that greatly improved accuracy over base rates showed that violent patients tended to be female, schizophrenic (nonparanoid type), and abusive of alcohol before admission. Violence is more common in treatment resistant psychotic inpatients than suggested by incident reports. Standardized definitions of violence are urged in order to accurately study its prevalence and correlates. Models combining both historical/demographic and clinical data may enhance prediction of violence.
Neuropsychopharmacology | 1995
William G. Honer; Geoffrey N. Smith; Jocelyne S. Lapointe; G. William MacEwan; Lili C. Kopala; Siemion Altman
Regional measures of cortical sulcal and ventricular enlargement on computed tomography scan were studied in a clinical sample of patients treated with clozapine. Cortical sulci were significantly enlarged in clozapine nonresponders compared to responders. The Clinical Global Impressions score at discharge was related to the size of the posterior frontal and lateral temporal sulci, with large sulci predicting a poorer response to clozapine treatment.
Journal of Psychopharmacology | 2002
Andrew K. Howard; Allen E. Thornton; Siemion Altman; William G. Honer
A case is reported of a 54-year-old female patient with schizophrenia and cognitive impairment. Her memory dysfunction improved following the addition of donepezil to quetiapine. The possible implications for future studies are reviewed.
Biological Psychiatry | 1996
Geoffrey N. Smith; G. William MacEwan; Siemion Altman; Barbara Meistrich; Jocelyne S. Lapointe; Lili C. Kopala; William G. Honer
Birth problems can lead to changes in brain morphology in the general population and an increased prevalence of both birth problems and altered brain morphology are found in patients with schizophrenia. The purpose of this study was to test the hypothesis that these two findings are related. Birth history and the size of ventricular and sulcal spaces from nine regions of the brain were assessed in 80 male subjects with schizophrenia. No differences were found between patients with and those without a history of birth problems for the size of any brain space; however, ventricular size increased significantly with age in patients who had no birth complications but not in patients with a history of birth problems. The size of cortical sulci increased with age in patients with and those without a history of birth problems. These results suggest that region-specific rates of change in size may identify clinically meaningful patients subgroups.
Archives of General Psychiatry | 2003
Herbert Y. Meltzer; Larry Alphs; Alan I. Green; A. Carlo Altamura; Ravi Anand; Alberto Bertoldi; Marc Bourgeois; Guy Chouinard; M. Zahur Islam; John M. Kane; Ranga R. Krishnan; Jean-Pierre Lindenmayer; Steven G. Potkin; Saide Altinsan; Siemion Altman; Likiana Avigo; Richard Balon; Vanda Benešová; Luis Bengochea; István Bitter; Elisabeth Bokowska; Bernardo Carpiniello; Daniel E. Casey; Giovanni B. Cassano; James C.-Y. Chou; Libor Chvila; Jean Dalery; Pedro L. Delgado; Liliana Dell'Osso; Carl Eisdorfer
Schizophrenia Research | 1997
Diane H. Fredrikson; James M. Steiger; G. William MacEwan; Siemion Altman; Lili C. Kopala; Sean W. Flynn; Peter F. Liddle; William G. Honer
Schizophrenia Research | 1997
Sean W. Flynn; G. William MacEwan; Siemion Altman; LiIi C. Kopala; Geoffrey N. Smith; William G. Honer
Schizophrenia Research | 1997
Thomas S. Ehmann; Deborah Ross; Tin Au; Geoffrey N. Smith; Sean W. Flynn; Siemion Altman; William G. Honer